Quick Comparison

GHK-CuMelatonin
Half-LifeTopical: variable (local effect) | Injectable: 1-2 hours40-60 minutes (oral); injectable forms have shorter half-life
Typical DosageTopical: 1-2% serum or cream once or twice daily. Injectable: 1-2 mg subcutaneous once daily. Microneedling: applied topically immediately after microneedling for enhanced penetration. Typical courses run 4-12 weeks.Oral (sleep): 0.5-5 mg once, 30-60 minutes before bed (lower doses of 0.5-1 mg are often more effective than higher doses). Extended-release forms available for sleep maintenance. Injectable: 10-20 mg for research protocols. High-dose IV: used in some anti-aging and oncology protocols.
AdministrationTopical (serums, creams), subcutaneous injection, or microneedlingOral (tablet, liquid, sublingual), injectable, or topical
Research Papers27 papers32 papers
Categories

Mechanism of Action

GHK-Cu

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide first isolated from human plasma in 1973 by Dr. Loren Pickart. Its copper-binding affinity is exceptionally high, and this copper chelation is central to its biological activity — the copper ion is coordinated by the histidine and lysine residues, creating a stable yet bioavailable copper delivery system.

The primary mechanism involves activation of copper-dependent enzymes critical for tissue structure and defense. Lysyl oxidase requires copper to catalyze the oxidative deamination of lysine and hydroxylysine residues in collagen and elastin precursors, forming the covalent cross-links (desmosine and isodesmosine) that give connective tissue its tensile strength and elasticity. Without adequate copper delivery, collagen fibers remain weak and poorly organized. Superoxide dismutase (Cu/Zn-SOD) uses the copper delivered by GHK-Cu for its antioxidant catalytic cycle, converting destructive superoxide radicals into hydrogen peroxide and oxygen.

Beyond copper delivery, GHK-Cu has remarkable gene-regulatory effects. Transcriptomic studies have shown it modulates the expression of over 4,000 human genes — approximately 6% of the genome. It upregulates genes involved in collagen synthesis (types I, III, V), elastin production, glycosaminoglycan synthesis, integrin and laminin expression, and growth factor production (TGF-β, VEGF, FGF). Simultaneously, it downregulates genes associated with inflammation, tissue destruction (matrix metalloproteinases), and fibrosis. In skin specifically, GHK-Cu stimulates dermal fibroblast proliferation, increases dermal thickness, improves skin density and firmness, and enhances wound contraction. It also promotes nerve outgrowth and blood vessel formation at wound sites. The breadth of its gene-regulatory activity suggests it acts as a master signaling molecule for tissue remodeling, essentially resetting gene expression patterns toward a younger, more regenerative profile.

Melatonin

Melatonin (N-acetyl-5-methoxytryptamine) is synthesized in the pineal gland from serotonin through a two-step pathway: N-acetyltransferase (AANAT) converts serotonin to N-acetylserotonin, and hydroxyindole O-methyltransferase (HIOMT) converts it to melatonin. AANAT activity is under direct control of the suprachiasmatic nucleus (SCN) master circadian clock — it is strongly suppressed by light (via the retinohypothalamic tract) and activated in darkness, creating the characteristic nocturnal melatonin surge that signals nighttime to every cell in the body.

Melatonin acts through two high-affinity G protein-coupled receptors: MT1 (MTNR1A) and MT2 (MTNR1B), both of which are Gi/o-coupled, inhibiting adenylyl cyclase and reducing cAMP when activated. MT1 receptors in the SCN mediate the acute sleep-promoting effect — their activation inhibits the firing rate of SCN neurons, reducing the alerting signal from the master clock and promoting sleepiness. MT2 receptors in the SCN mediate circadian phase-shifting — their activation during the biological evening advances the clock phase (useful for jet lag and delayed sleep phase), while activation during the biological morning delays it. This dual receptor mechanism explains why melatonin both promotes acute sleepiness and shifts circadian timing.

Beyond sleep, melatonin is one of the most potent endogenous antioxidants. It directly scavenges hydroxyl radicals, superoxide anions, hydrogen peroxide, and peroxynitrite through electron donation. Uniquely, melatonin's antioxidant cascade is amplified — its metabolites (cyclic 3-hydroxymelatonin, AFMK, AMK) are themselves antioxidants, so each melatonin molecule can neutralize up to 10 reactive oxygen species in a cascade. Melatonin also upregulates antioxidant enzymes (superoxide dismutase, glutathione peroxidase, catalase) and downregulates pro-oxidant enzymes (nitric oxide synthase, lipoxygenase). In the immune system, MT1 receptors on T helper cells, natural killer cells, and eosinophils modulate immune function — melatonin generally enhances Th1 cellular immunity, increases NK cell activity, and augments antibody responses to vaccination, which has led to interest in melatonin as an immunomodulator in aging and cancer.

Risks & Safety

GHK-Cu

Common

mild skin irritation, redness, bruising, injection site irritation.

Serious

theoretical risk of copper accumulation with long-term high doses; no long-term safety data for injectable use.

Rare

allergic reactions, contact dermatitis.

Melatonin

Common

daytime drowsiness, headache, vivid or unusual dreams, mild dizziness, next-morning grogginess at higher doses.

Serious

potential suppression of your body's own melatonin production with long-term use, drug interactions with blood thinners (warfarin) and immunosuppressants.

Rare

depressed mood, sleep-walking, allergic reactions.

Full Profiles